Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, an investigational therapy for Parkinson’s disease. This decision is influenced by positive data from the phase 2b PADOVA study, ongoing open-label extensions (OLEs) of PADOVA as well as phase 2 PASADENA studies. Multiple endpoints from the PADOVA and OLE studies […]
The post Roche advances treatment for Parkinson’s disease appeared first on Pharmafile.
